Department of Dermatology at University of L'Aquila, L'Aquila, Italy.
J Am Acad Dermatol. 2013 Dec;69(6):947-53. doi: 10.1016/j.jaad.2013.08.017. Epub 2013 Oct 2.
Few data exist on the relationship between psoriasis and melanocytic lesions.
We sought to investigate number of melanocytic nevi in psoriatic patients compared with control subjects and its relationship with disease severity and treatment.
We performed a prospective study in 189 psoriatic patients and 189 control subjects. Sociodemographic and clinical data were recorded for all participants.
As compared with control subjects, patients had fewer nevi overall [χ(2)(5) = 52.24, P < .001], fewer nevi less than 5 mm [χ(2)(4) = 60.28, P < .001], and fewer congenital nevi [χ(2)(1) = 10.41, P = .002]; no differences in atypical nevi and family history of cancer, including melanoma, were observed. Among psoriatic patients, number of biologics used was a risk factor for a higher nevus count [odds ratio 1.35 (95% CI 1.04-1.76), P = .02] whereas disease severity did not correlate with number of nevi.
Low number of psoriatic patients naïve to systemic therapies was a limitation.
Psoriatic patients have fewer nevi than control subjects. Frequency of nevi in psoriatic patients is related to treatment, not to disease severity.
目前关于银屑病与黑素细胞病变之间的关系的数据较少。
我们旨在调查银屑病患者与对照组黑素细胞痣的数量,并研究其与疾病严重程度和治疗的关系。
我们对 189 例银屑病患者和 189 例对照者进行了前瞻性研究。所有参与者均记录了社会人口统计学和临床数据。
与对照组相比,患者的痣总数较少[χ(2)(5) = 52.24,P <.001],直径小于 5 毫米的痣较少[χ(2)(4) = 60.28,P <.001],先天性痣较少[χ(2)(1) = 10.41,P =.002];未观察到不典型痣和癌症家族史(包括黑色素瘤)存在差异。在银屑病患者中,使用生物制剂的数量是痣数量较高的危险因素[比值比 1.35(95%CI 1.04-1.76),P =.02],而疾病严重程度与痣数量无关。
接受过系统治疗的银屑病患者数量较少是一个局限性。
银屑病患者的痣比对照组少。银屑病患者痣的频率与治疗有关,与疾病严重程度无关。